Solid Biosciences Inc.
SLDB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.22 | 0.10 | 0.06 | -0.99 |
| FCF Yield | -5.76% | -8.24% | -13.03% | -13.93% |
| EV / EBITDA | -11.96 | -8.78 | -1.51 | -3.77 |
| Quality | ||||
| ROIC | -20.03% | -14.82% | -12.59% | -24.72% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.95 | 0.81 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 11.20% | -18.18% | -7.13% | -25.82% |
| Safety | ||||
| Net Debt / EBITDA | 0.87 | 2.97 | 4.82 | 1.33 |
| Interest Coverage | 0.00 | -694.88 | -589.00 | -531.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,096.79 | -1,423.86 | 0.00 |